1. Promoting innovation through research networks: IAVI and our global partners Holly Wong International AIDS Vaccine Initiative (IAVI) August 3, 2008

2. What is IAVI? Mission To ensure the development of a safe, effective, accessible, preventive HIV vaccine for use throughout the world Integrated model of R&D Emphasis on discovery research and product development – targeting gaps and promoting rational vaccine design Industrial project management Policy & advocacy linked (lab bench to the G8) Sustained commitment to developing countries Founded in 1996 225 staff, 5 offices (Amsterdam, Delhi, Johannesburg, Nairobi, NY), active in 24 countries $90.5 million annual budget Largest global organization solely focused on HIV vaccine; 2nd largest program 40+ R&D partnerships Trials in 11 countries

3. Improving the global pipeline means shifting the emphasis to vaccine discovery Collaborative research consortia focus on key challenges Neutralizing Antibody Consortium (NAC) design of immunogens to elicit broadly neutralizing antibodies against HIV; Live Attenuated Consortium (LAC) determine mechanism of protection of live attenuated SIV vaccines and HIV elite controllers to inform vaccine design; Vectors Consortium (VEC) in Collaboration with the Gates Foundation systematic design, comparison, and prioritization of novel viral-vector based vaccines.

4. Network of labs -IAVI Vaccine Development Lab -IAVI Human Immunology Lab -Programs at Oxford, Scripps, DBT (India) IAVI’s global partnerships help build an integrated R&D process Scientific consortia -Neutralizing Antibodies -Vector Design -SIV-Live Attenuated Innovation Fund -Advance early-stage technology -Wide range of disciplines Research partners (proposed) Clinical trial sites San Diego, CA - La Jolla Center Boston - Harvard/MIT IAVI Brooklyn Lab London - Core Lab Tskukuba City, Japan - DNAVEC Bangalore, India - India DBT Pune Chennai Cape Town, SA Soweto, SA Medunsa, SA Lusaka, Zambia Kilifi, Kenya Nairobi, Kenya Kangemi, Kenya Entebbe, Uganda Masaka, Uganda Kigali, Rwanda

5. Europe and AIDS vaccine R&D: A strong institutional network Europe’s contributions (up to 2007) European govt investment doubled in 5 years (US $39m to $79m) UK, Russia, France, Ireland and EC in the top 15 funders EC funds 12 trans-national vaccine consortia -- 132 institutions, 22 countries (US$23m) Europe has much to offer global search  More biotechs in Europe (>1,200) than US (~1,000)  World’s largest developers involved -- GSK, Sanofi and Novartis  Large public bodies engaged -- ANRS (FR), MRC (UK), and SIVR (CH)  Europe’s R&D players participate at global level  EDCTP has ~€7m for trials in sub-Saharan Africa  Research consortia, e.g. NAC: Oxford University  1/3 of The CAVD primary investigators are Europeans (based in EU)

6. Europe and AIDS vaccine R&D: A strong institutional network IAVI’s industry partners  Arexis, Sweden  Berna, Switzerland  Bioption, Sweden  Biovex, UK  Crucell, Netherlands  Cobra, UK  FIT Biotech, Finland  GSK Biologicals, Belgium  IDT, Germany  Inovio, Norway  Symphogen, Denmark  Transgene, France IAVI’s academic partners  Centre d’Immunologie de Marseille-Luminy, France  Imperial College, UK  Karolinska Institute, Sweden  Medical Research Council, UK  St. Georges, Uni of London, UK  Statens Serum Institute, Denmark  University of Amsterdam  University of Oxford, UK

7. Europe and AIDS vaccine R&D: A strong institutional network IAVI’s European civil society partners  AIDS Fondet, Denmark  AIDS Fonds, Netherlands  Association of European Parliamentarians for Africa, Netherlands  AIDS Tukik (Finnish AIDS Council), Finland  Commonwealth Medical Association Trust, UK  Deutsche AIDS Stiftung, Germany  Fondation Marcel Mérieux, France  Ecumenical Advocacy Alliance, Switzerland  Fondation Marcel Mérieux, France  Global Network of People Living with HIV/AIDS, Netherlands  Global Sida, Spain  National AIDS Trust, UK  Noah's Ark, Sweden  Planeta Salud, Spain  SENSOA, Belgium  STOP AIDS NOW!, Netherlands  World AIDS Campaign International, Netherlands …hailing from 10 countries 17 organizations…

8. Brazil and AIDS vaccine R&D: A rapidly expanding commitment Brazil’s strengths and engagement in HIV/AIDS:  Global leadership role on HIV/AIDS issues  Vibrant, self-sufficient public health system; robust manufacturing capacity  Participation in 6 Phase I and Phase II clinical trials since 2001 with international partners (e.g. NIH, NIAID, HVTN, DAIDS, VRC) Opportune time to involve Brazil in global search for AIDS vaccines: Efforts to strengthen biotechnology and medical innovation in Brazil New National AIDS Vaccine Plan IAVI in Brazil:  Supporting launch of National AIDS Vaccine plan, promoting national advocacy and education efforts, providing technical assistance for Government mapping project  Conducting policy research on modeling the potential impact and accelerating the R&D of AIDS vaccines

9. China and AIDS vaccine R&D: Potential for a major new player  Dynamic health biotechnology market  Significant government funding for R&D  Growing political and economic power From 1999 to 2003, China’s R&D expenditures grew 24% annually (2x India) Pharma patent applications from Chinese companies: 283 to 1,696 per year Biotech industry grew 30% annually to $3 billion from 2000 to 2005 IAVI’s current and planned work in China: an integrated program R&D  Technical assistance to laboratories  Improved project management Political environment  Vaccine preparedness  Media training Policy  Impact modeling  Supporting work on incentive mechanisms and funding initiatives

10. Technical and scientific capacity needs to be sustained and expanded, but not in isolation The field also needs: Political leadership and commitment that is sustained for the long term National ownership of the AIDS vaccine agenda at all levels Innovative policy in the North and the South to support scientific efforts Full community engagement through education, transparency and consultation Today always linked to tomorrow: Integration within a comprehensive response to AIDS – better use of today’s tools, better tools for tomorrow. Build capacity now, but also work to ensure that new generations of scientists are available for future research. Long-term partnerships to ensure continuous stream of ideas and funding. Flexibility to respond to changes and needs in local contexts. A dual mission: accelerating development of a vaccine AND ensuring access